New Risk • Jun 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.16b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • May 07
First quarter 2026 earnings released: NT$0.13 loss per share (vs NT$0.27 loss in 1Q 2025) First quarter 2026 results: NT$0.13 loss per share (improved from NT$0.27 loss in 1Q 2025). Revenue: NT$54.9m (up 16% from 1Q 2025). Net loss: NT$15.8m (loss narrowed 53% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Mar 06
BioGend Therapeutics Co., Ltd. has filed a Follow-on Equity Offering in the amount of TWD 30.6 million. BioGend Therapeutics Co., Ltd. has filed a Follow-on Equity Offering in the amount of TWD 30.6 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 850,000
Price\Range: TWD 36 Announcement • Feb 25
BioGend Therapeutics Co., Ltd., Annual General Meeting, May 27, 2026 BioGend Therapeutics Co., Ltd., Annual General Meeting, May 27, 2026. Location: 4 floor building. h no,3-2, yuan ou st., nangang district, taipei city Taiwan Reported Earnings • Feb 25
Full year 2025 earnings released: NT$0.69 loss per share (vs NT$0.95 loss in FY 2024) Full year 2025 results: NT$0.69 loss per share (improved from NT$0.95 loss in FY 2024). Revenue: NT$222.3m (up 33% from FY 2024). Net loss: NT$84.6m (loss narrowed 27% from FY 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman & GM Te-Li Chen was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Nov 07
Third quarter 2025 earnings released: NT$0.05 loss per share (vs NT$0.26 loss in 3Q 2024) Third quarter 2025 results: NT$0.05 loss per share (improved from NT$0.26 loss in 3Q 2024). Revenue: NT$61.7m (up 39% from 3Q 2024). Net loss: NT$6.87m (loss narrowed 78% from 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 23% per year. New Risk • Oct 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. New Risk • Sep 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 08
Second quarter 2025 earnings released: NT$0.19 loss per share (vs NT$0.28 loss in 2Q 2024) Second quarter 2025 results: NT$0.19 loss per share (improved from NT$0.28 loss in 2Q 2024). Revenue: NT$52.7m (up 42% from 2Q 2024). Net loss: NT$23.2m (loss narrowed 34% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year. Reported Earnings • May 08
First quarter 2025 earnings released: NT$0.27 loss per share (vs NT$0.089 loss in 1Q 2024) First quarter 2025 results: NT$0.27 loss per share (further deteriorated from NT$0.089 loss in 1Q 2024). Revenue: NT$47.5m (up 34% from 1Q 2024). Net loss: NT$33.3m (loss widened 204% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • May 01
BioGend Therapeutics Co., Ltd. to Report Q1, 2025 Results on May 07, 2025 BioGend Therapeutics Co., Ltd. announced that they will report Q1, 2025 results on May 07, 2025 New Risk • Apr 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 04
Full year 2024 earnings released: NT$0.95 loss per share (vs NT$1.30 loss in FY 2023) Full year 2024 results: NT$0.95 loss per share (improved from NT$1.30 loss in FY 2023). Revenue: NT$167.6m (up 53% from FY 2023). Net loss: NT$116.5m (loss narrowed 26% from FY 2023). Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year. Announcement • Feb 26
BioGend Therapeutics Co., Ltd., Annual General Meeting, May 27, 2025 BioGend Therapeutics Co., Ltd., Annual General Meeting, May 27, 2025. Location: 4 floor building. h no,3-2, yuan ou st., nangang district, taipei city Taiwan Announcement • Feb 18
BioGend Therapeutics Co., Ltd. to Report Q4, 2024 Results on Feb 25, 2025 BioGend Therapeutics Co., Ltd. announced that they will report Q4, 2024 results at 9:00 AM, Taipei Standard Time on Feb 25, 2025 Reported Earnings • Nov 14
Third quarter 2024 earnings released: NT$0.25 loss per share (vs NT$0.35 loss in 3Q 2023) Third quarter 2024 results: NT$0.25 loss per share (improved from NT$0.35 loss in 3Q 2023). Revenue: NT$44.3m (up 110% from 3Q 2023). Net loss: NT$31.4m (loss narrowed 26% from 3Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 29% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 15% per year. Announcement • Nov 02
BioGend Therapeutics Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024 BioGend Therapeutics Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024 Reported Earnings • Aug 14
Second quarter 2024 earnings released: NT$0.28 loss per share (vs NT$0.26 loss in 2Q 2023) Second quarter 2024 results: NT$0.28 loss per share (further deteriorated from NT$0.26 loss in 2Q 2023). Revenue: NT$37.3m (down 3.1% from 2Q 2023). Net loss: NT$34.9m (loss widened 16% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 13% per year. Announcement • Aug 02
BioGend Therapeutics Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024 BioGend Therapeutics Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024 Announcement • May 29
BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System (Qms) Manufacturing License BioGend Therapeutics Co., Ltd. announced that company's Hsinchu factory has passed the domestic medical device quality management system (QMS) manufacturing license. The TFDA sent inspector to the factory for an on-site inspection on February 27, 2024. On May 28, 2024 BioGend received notification from the FDA that BioGend's Hsinchu factory complies with the requirements of Taiwan's Quality Management System for Medical Devices (QMS) and has been granted a manufacturing license. The license number is QMS2268. Reported Earnings • May 12
First quarter 2024 earnings released First quarter 2024 results: Revenue: NT$35.6m (up 229% from 1Q 2023). Net loss: NT$11.0m (loss narrowed 79% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 06
Full year 2023 earnings released: NT$1.30 loss per share (vs NT$1.79 loss in FY 2022) Full year 2023 results: NT$1.30 loss per share (improved from NT$1.79 loss in FY 2022). Revenue: NT$109.9m (up 250% from FY 2022). Net loss: NT$156.3m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 27
BioGend Therapeutics Co., Ltd., Annual General Meeting, May 28, 2024 BioGend Therapeutics Co., Ltd., Annual General Meeting, May 28, 2024. Location: Conference Room, 4F, Building H, No. 3-2, Yuanqu Street Nangang District Taipei Taiwan Agenda: To report the business of FY 2023; to consider Audit Committee's review report on the FY 2023 audited financial; to consider The implementation report of the sound business plan is submitted for review; to consider The private placement report is submitted for review; to consider To report FY 2023 Directors' remuneration; to accept FY 2023 Business Report and Financial Statements; to consider 2023 The Company's Loss Appropriation Statement; to propose the issuance plan of private placement for ordinary shares; to approve the lifting of non-competition restrictions for directors. New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$81m revenue, or US$2.6m). Reported Earnings • Nov 08
Third quarter 2023 earnings released: NT$0.36 loss per share (vs NT$0.51 loss in 3Q 2022) Third quarter 2023 results: NT$0.36 loss per share (improved from NT$0.51 loss in 3Q 2022). Revenue: NT$21.1m (up 120% from 3Q 2022). Net loss: NT$42.4m (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. New Risk • Aug 10
New major risk - Revenue and earnings growth Earnings have declined by 0.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.5% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$70m revenue, or US$2.2m). Reported Earnings • Aug 09
Second quarter 2023 earnings released: NT$0.26 loss per share (vs NT$0.33 loss in 2Q 2022) Second quarter 2023 results: NT$0.26 loss per share (improved from NT$0.33 loss in 2Q 2022). Net loss: NT$30.0m (loss narrowed 13% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 1% per year. Reported Earnings • Mar 31
Full year 2022 earnings released: NT$1.79 loss per share (vs NT$1.37 loss in FY 2021) Full year 2022 results: NT$1.79 loss per share (further deteriorated from NT$1.37 loss in FY 2021). Net loss: NT$184.5m (loss widened 33% from FY 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 16
Third quarter 2022 earnings released: NT$0.50 loss per share (vs NT$0.39 loss in 3Q 2021) Third quarter 2022 results: NT$0.50 loss per share (further deteriorated from NT$0.39 loss in 3Q 2021). Net loss: NT$52.0m (loss widened 33% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 13
Third quarter 2022 earnings released: NT$0.50 loss per share (vs NT$0.39 loss in 3Q 2021) Third quarter 2022 results: NT$0.50 loss per share (further deteriorated from NT$0.39 loss in 3Q 2021). Net loss: NT$52.0m (loss widened 33% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 15
Second quarter 2022 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2021) Second quarter 2022 results: NT$0.33 loss per share (up from NT$0.38 loss in 2Q 2021). Net loss: NT$34.5m (loss narrowed 9.9% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • May 14
First quarter 2022 earnings released: NT$0.43 loss per share (vs NT$0.47 loss in 1Q 2021) First quarter 2022 results: NT$0.43 loss per share (up from NT$0.47 loss in 1Q 2021). Net loss: NT$44.6m (loss narrowed 4.7% from 1Q 2021). Reported Earnings • Nov 13
Third quarter 2021 earnings released: NT$0.39 loss per share (vs NT$0.48 loss in 3Q 2020) Third quarter 2021 results: Net loss: NT$39.2m (loss narrowed 11% from 3Q 2020). Reported Earnings • May 12
First quarter 2021 earnings released: NT$0.47 loss per share (vs NT$0.42 loss in 1Q 2020) First quarter 2021 results: Net loss: NT$46.8m (loss widened 34% from 1Q 2020). Announcement • Mar 18
BioGend Therapeutics Co., Ltd., Annual General Meeting, Jun 08, 2021 BioGend Therapeutics Co., Ltd., Annual General Meeting, Jun 08, 2021. Reported Earnings • Mar 17
Full year 2020 earnings released: NT$1.67 loss per share (vs NT$2.01 loss in FY 2019) Full year 2020 results: Net loss: NT$145.6m (loss narrowed 11% from FY 2019). Is New 90 Day High Low • Feb 18
New 90-day low: NT$27.75 The company is down 29% from its price of NT$39.10 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Is New 90 Day High Low • Jan 28
New 90-day low: NT$31.20 The company is down 24% from its price of NT$40.80 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 26
New 90-day low: NT$38.75 The company is down 6.0% from its price of NT$41.15 on 28 August 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: NT$0.48 loss per share Third quarter 2020 results: Net loss: NT$44.3m (flat on 3Q 2019). 
